Sirona down and out on prospects of finding a suitor for diabetes med

13 Jul 2023
www.fiercebiotech.com
License out/inPhase 1
Sirona down and out on prospects of finding a suitor for diabetes med
Preview
Source: FierceBiotech
For more than a year, Sirona has said it was in discussions with companies that could license its diabetes med as a treatment for animals.
Sirona is not beating around the bush: the company has had a difficult time selling its diabetes med and is now “less confident” it will score a licensing deal.
The candid about-face came in a corporate update Thursday, with the Canadian biotech saying that efforts to find a partner for TFC-039 have been “notably slow primarily due to the challenges in obtaining the clinical data held by our external partner.”
That’s a not-so-subtle dig at Wanbang Biopharmaceuticals in China, which Sirona has maintained an on-again, off-again relationship with for years. Sirona first out-licensed China rights for TFC-039 to Wanbang in 2014 but the latter company stopped further development in 2021 after completing a phase 1 trial. The two companies inked a new global partnership a year later, in November 2022, though the terms of the deal were not spelled out. Sirona only pocketed $1.5 million in upfront and milestone payments from the first China-focused pact.
The med is a sodium-glucose cotransporter 2 (SGLT2) inhibitorsodium-glucose cotransporter 2 (SGLT2) inhibitor, a class of metabolic medicines that’s churned out treatments like Johnson & Johnson’s Invokana and AstraZeneca and Bristol Myers Squibb’s Forxiga. Sirona says that while looking for someone to help take TFC-039 forward, it has made “significant new advancements in the field of SGLT2 inhibitorsSGLT2 inhibitors.” What those advancements were, exactly, the biotech didn’t say. Evidently, they’re enough that the company isn’t axing all work on the class, saying that they’ll advance the new discoveries that have been made.
According to the company's website, Sirona was in late-stage discussions with four “major interested parties” from the animal health sector. And it’s been in the process of securing a patent on a new indication that’s yet to be unveiled.
Sirona’s latest update today suggests a bleak outlook for the med, which is the company’s lead foray into the pharmaceutical business after Sirona initially established itself as a cosmetic company. The biotech is also testing anti-viral compounds in collaboration with the International Centre for Genetic Engineering and Biotechnology, a research outpost originally launched by the United Nations that’s been independent for almost 30 years. Sirona says results of those tests “are expected within the next two months.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.